Jeffrey K Aronson
1980–2025 年に発表
- 92
- 論文数
- 23,040
- 被引用数
- 63
- h 指数
- 89
- i10 指数
被引用数
引用元
国・地域
機関
- University of Oxford0.9%
- Inserm0.5%
- Harvard University0.5%
- The University of Sydney0.5%
- University College London0.4%
- University of Toronto0.3%
- その他96.9%
分野
- Medicine59.4%
- Pharmacology, Toxicology and Pharmaceutics8.3%
- Biochemistry, Genetics and Molecular Biology6.6%
- Computer Science5.8%
- Health Professions5.6%
- Decision Sciences1.8%
- その他12.5%
トピック
- Pharmacovigilance and Adverse Drug Reactions3.6%
- Medication Adherence and Compliance3.3%
- Pharmaceutical Practices and Patient Outcomes2.9%
- Computational Drug Discovery Methods2.7%
- COVID-19 Clinical Research Studies1.7%
- Patient Safety and Medication Errors1.4%
- その他84.4%
共著者
- Carl Heneghan22
- R E Ferner17
- Georgia C. Richards9
- Kamal R Mahtani9
- Igho Onakpoya8
- Rafael Perera5
- Richard Hobbs5
- Ben Goldacre4
- Constantinos Koshiaris4
- Daniel M. Laskin4
- Dennis P. Orgill4
- Jeremy Howick4
- Nia Roberts4
- Paul Glasziou4
- Riaz Agha4
- Richard Stevens4
- Somprakas Basu4
- Abdulrahman Alsawadi3
- Boris Kirshtein3
- Carl J Heneghan3
- Clare Bankhead3
- Diana Miguel3
- Jack W. O’Sullivan3
- James Chi‐Yong Ngu3
全論文
- A NEW TAXONOMY FOR DESCRIBING AND DEFINING ADHERENCE TO MEDICATIONS
著者: Bernard Vrijens, Sabina De Geest, Dyfrig Hughes, Przemysław Kardas, J. Demonceau, Todd Ruppar, Fabienne Dobbels, Emily Fargher, Val Morrison, Paweł Lewek, Michał Matyjaszczyk, Comfort Mshelia, Wendy Clyne, Jeffrey K Aronson, John Urquhart, ABC project team - British Journal of Clinical Pharmacology 2011 被引用: 1,996
- Adverse drug reactions: definitions, diagnosis, and management
著者: I. Ralph Edwards, Jeffrey K Aronson - The Lancet 2000 被引用: 2,972
- CARE guidelines for case reports: explanation and elaboration document
著者: D. Riley, Melissa S. Barber, Gunver S. Kienle, Jeffrey K Aronson, Tido von Schoen-Angerer, Peter Tugwell, Helmut Kiene, Mark Helfand, Douglas G. Altman, Harold C. Sox, Paul G. Werthmann, David Moher, Richard A. Rison, Larissa Shamseer, Christian A. Koch, Gordon H. Sun, Patrick Hanaway, Nancy L. Sudak, Marietta Kaszkin-Bettag, James E. Carpenter, Joel Gagnier - Journal of Clinical Epidemiology 2017 被引用: 2,086
- Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
著者: Igho Onakpoya, Carl J Heneghan, Jeffrey K Aronson - BMC Medicine 2016 被引用: 618
- Biomarkers—A General Review
著者: Jeffrey K Aronson, R E Ferner - Current Protocols in Pharmacology 2017 被引用: 401
- STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery
著者: Riaz Agha, Ali Abdall-Razak, Eleanor Crossley, Naeem Dowlut, Christos Iosifidis, Ginimol Mathew, Beamishaj, Mohammad Bashashati, Frederick H. Millham, Dennis P. Orgill, Ashraf Noureldin, Iain J. Nixon, Abdulrahman Alsawadi, Patrick J. Bradley, Salvatore Giordano, Daniel M. Laskin, Somprakas Basu, Maximilian J. Johnston, Oliver J. Muensterer, Indraneil Mukherjee, James Chi‐Yong Ngu, Michele Valmasoni, Duilio Pagano, Baskaran Vasudevan, R. David Rosin, James McCaul, Jörg Albrecht, Jerome R. Hoffman, Mangesh A. Thorat, Samuele Massarut, Achilles Thoma, Boris Kirshtein, Raafat Yahia Afifi, Naheed Farooq, Ben Challacombe, Prathamesh Pai, Benjamin Perakath, Hüseyin Kadioğlu, Jeffrey K Aronson, Kandiah Raveendran, David Machado-Aranda, Roberto Klappenbach, Donagh Healy, Diana Miguel, Cláudio Rodrigues Leles, M Hammad Ather - International Journal of Surgery 2019 被引用: 1,592
- Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses
著者: Ting Cai, Lucy Abel, Oliver Langford, G Monaghan, Jeffrey K Aronson, Richard Stevens, Sarah Lay‐Flurrie, Constantinos Koshiaris, Richard J. McManus, Richard Hobbs, James P Sheppard - BMJ 2021 被引用: 221
- Overdiagnosis: what it is and what it isn’t
著者: John Brodersen, Lisa M. Schwartz, Carl Heneghan, Jack W. O’Sullivan, Jeffrey K Aronson, Steven Woloshin - BMJ evidence-based medicine 2018 被引用: 363
- Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy
著者: Adam S. Darwich, Thomas M. Polasek, Jeffrey K Aronson, Kayode Ogungbenro, Daniel F. B. Wright, Brahim Achour, Jean‐Luc Reny, Youssef Daali, Birgit Eiermann, Jack Cook, Lawrence J. Lesko, Andrew J. McLachlan, Amin Rostami‐Hodjegan - The Annual Review of Pharmacology and Toxicology 2020 被引用: 168
- Summarising good practice guidelines for data extraction for systematic reviews and meta-analysis
著者: Kathryn Taylor, Kamal R Mahtani, Jeffrey K Aronson - BMJ evidence-based medicine 2021 被引用: 107
- Medical Devices: Definition, Classification, and Regulatory Implications
著者: Jeffrey K Aronson, Carl Heneghan, R E Ferner - Drug Safety 2019 被引用: 104
- Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
著者: Igho Onakpoya, Carl Heneghan, Jeffrey K Aronson - BMC Medicine 2016 被引用: 169
- Defining ‘nutraceuticals’: neither nutritious nor pharmaceutical
著者: Jeffrey K Aronson - British Journal of Clinical Pharmacology 2016 被引用: 269
- Catalogue of bias: attrition bias
著者: David Nunan, Jeffrey K Aronson, Clare Bankhead - BMJ evidence-based medicine 2018 被引用: 200
- Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists
著者: Jeffrey K Aronson, A. Richard Green - British Journal of Clinical Pharmacology 2020 被引用: 92
- Clarification of Terminology in Drug Safety
著者: Jeffrey K Aronson, R E Ferner - Drug Safety 2005 被引用: 325
- Signals of Adverse Drug Reactions Communicated by Pharmacovigilance Stakeholders: A Scoping Review of the Global Literature
著者: Daniele Sartori, Jeffrey K Aronson, G. Niklas Norén, Igho Onakpoya - Drug Safety 2022 被引用: 34
- The Need for Randomization in Animal Trials: An Overview of Systematic Reviews
著者: Jennifer Hirst, Jeremy Howick, Jeffrey K Aronson, Nia Roberts, Rafael Perera, Constantinos Koshiaris, Carl Heneghan - PLoS ONE 2014 被引用: 293
- Redefining rapid reviews: a flexible framework for restricted systematic reviews
著者: Annette Plüddemann, Jeffrey K Aronson, Igho Onakpoya, Carl Heneghan, Kamal R Mahtani - BMJ evidence-based medicine 2018 被引用: 149
- Naltrexone–bupropion (Mysimba) in management of obesity: A systematic review and meta‐analysis of unpublished clinical study reports
著者: Igho Onakpoya, Joseph Lee, Kamal R Mahtani, Jeffrey K Aronson, Carl Heneghan - British Journal of Clinical Pharmacology 2020 被引用: 76
- All-Cause and Cardiovascular Mortality in Middle-Aged People With Type 2 Diabetes Compared With People Without Diabetes in a Large U.K. Primary Care Database
著者: Kathryn Taylor, Carl Heneghan, Andrew J. Farmer, Alice Fuller, Amanda Adler, Jeffrey K Aronson, Richard Stevens - Diabetes Care 2013 被引用: 170
- Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions
著者: Manfred Hauben, Jeffrey K Aronson - Drug Safety 2009 被引用: 161
- Evidence-based mechanistic reasoning
著者: Jeremy Howick, Paul Glasziou, Jeffrey K Aronson - Journal of the Royal Society of Medicine 2010 被引用: 119
- Medication errors: definitions and classification
著者: Jeffrey K Aronson - British Journal of Clinical Pharmacology 2009 被引用: 410